Navigation Links
Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
Date:10/25/2011

BEDMINSTER, N.J., Oct. 25, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Timothy J. Maines has joined the Company as Vice President of Quality.  In this newly created position, reporting directly to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines will be responsible for Quality, Validation and CMC development at Omthera.  

Mr. Maines brings to the Company more than 25 years of pharmaceutical, medical device and biologic experience in both the U.S. and European Union, with additional skills in biochemistry, chemistry and virology.

Commenting on today's news, Drs. Machielse stated, "Timothy is a proven Quality Executive with an extensive range of expertise in start-up, clinical and commercial operations. As Vice President of Quality, Timothy will help build a strong infrastructure for Omthera's manufacturing and quality practices.  As such, we are delighted to welcome him to the Company. His experience in bringing specialty products to market will be key as we pursue the ultimate commercialization of Epanova™, as demonstrated by Tim's contributions to the approval of ATryn and OP-1 Implant."

Prior to joining Omthera, from November 2007 until recently, Mr. Maines was Vice President Corporate Quality Assurance at MedImmune, LLC, where he oversaw a 200 person QA Operations team at six GMP manufacturing facilities in the U.S., UK and Netherlands.  From March 2000 to October 2007, Mr. Maines held various positions at GTC Biotherapeutics, including Vice President of Quality. While there, he was closely involved in the approval of the first product produced in transgenic dairy animals.

Mr. Maines' experience also includes Director of Quality at Stryker Corporation-Biotech Division; Director of Quality Assurance/Quality Control and Manager of Validation at Creative BioMolecules; and Manager of Quality Assurance at BioProcess Technologies, among others.  Mr. Maines earned a Bachelor of Science in Biology/Microbiology from Gannon University.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). In August, 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  For more information, please visit www.omthera.com.Omthera Contacts:Omthera Media Relations:Douglas Carr

Eric GoldmanFinancial Controller

Rx Communications GroupOmthera Pharmaceuticals

917-322-2563908-741-4323

egoldman@rxir.comDCarr@Omthera.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference
2. Timothy G. Hayes Appointed Head of Global Business Development for Bayer HealthCare Consumer Care
3. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
4. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
5. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
6. Timothy Cote, MD, MPH, Joins NORD as Chief Medical Officer
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
(Date:3/29/2017)... 2017 Research and Markets has announced the addition ... Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... in 2016. There are currently three proton therapy centers in ... patients. In Italy , the first patients were treated ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... Policy, Patients Treated at Proton Therapy Centers & Forecast" report to ... The South ... its current market size in 2016. The Untapped Proton Therapy Market for ... Billion USD in 2016. Proton Therapy plays an important ...
Breaking Medicine Technology:
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
Breaking Medicine News(10 mins):